19 Supported by research
Inadequate sleep increases cortisol levels, induces inflammation, and increases insulin resistance.
"But the inadequate sleep that we receive through upregulating cortisol and being an inflammatory event, increasing insulin resistance" (said at 0:12:17)
The host's statement that inadequate sleep upregulates cortisol, induces inflammation, and increases insulin resistance is supported by clinical and metabolic literature. Syntheses of experimental and epidemiological evidence show that sleep loss elevates cortisol levels, activates neuroendocrine and inflammatory pathways, and impairs insulin sensitivity (increasing insulin resistance). Although acute short-term sleep restriction studies in laboratory settings show varying immediate effects on specific circulating inflammatory cytokines and hypothalamic-pituitary-adrenal axis markers, the established body of evidence connects insufficient sleep to elevated cortisol, systemic inflammatory signaling, and metabolic dysfunction including insulin resistance.
- supports: Effects of sleep deprivation on sarcopenia and obesity: A narrative review of randomized c… (Journal of frailty, sarcopenia and falls 2021) · cited 22x in the literature
"Concomitantly, the metabolic damage caused by lower testosterone and higher cortisol levels may stimulate systemic inflammation, insulin resistance, and suppress pathways involved in muscle protein synthesis." (abstract, passage verified)
pubmedfull study (doi) - supports: Sleep loss as a cardiometabolic risk factor: a narrative review of clinical and public hea… (Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2026) · cited 1x in the literature
"Sleep loss activates the sympathetic nervous system and elevates cortisol, while suppressing growth hormone, thereby promoting vasoconstriction, endothelial dysfunction, and cardiac remodeling." (abstract, passage verified)
pubmedfull study (doi)
Perimenopause lasts on average for 2 to 8 years, typically between the ages of 35 and 51.
"she looks at perimenopause, which on average lasts for women for 2 to 8 years, typically between 35 and 51" (said at 0:18:11)
Large prospective cohort data, such as the multiethnic Study of Women's Health Across the Nation (SWAN), show that the menopausal transition (perimenopause) typically lasts around 4 to 8 years on average, with median duration ranging from approximately 4.4 to 8.6 years depending on age of onset. Perimenopause generally starts in a woman's late 30s to 40s (around ages 35–45) and concludes at natural menopause, which occurs at an average age of 51.
Research by Lisa Mosconi shows that women begin developing cerebral glucose hypometabolism in perimenopause, preceding Alzheimer's disease diagnosis by over 25 years.
"And what she's found is that women, starting in perimenopause, have these changes in the brain that predate the diagnosis of Alzheimer's by 25-plus years. Now, much of your work is about, okay, what can we do to prevent that arc to Alzheimer's disease? And what I think is so interesting about her work is that she's seen these changes—I think of it as kind of a slowdown in metabolism of the brain, she calls it cerebral hypometabolism, meaning that glucose just isn't taken up in the same way." (said at 0:18:28)
Neuroimaging research led by Dr. Lisa Mosconi demonstrated that women transitionally develop cerebral glucose hypometabolism in Alzheimer's disease-vulnerable brain regions starting during perimenopause (typically in their 40s and 50s), several decades before the typical age of clinical Alzheimer's disease diagnosis (typically age 75+). Using 18F-FDG-PET scans, these observational studies showed that perimenopausal and postmenopausal women exhibit significant reductions in brain glucose metabolism compared to premenopausal controls and age-matched men.
- supports: Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. (Neurology 2017) · cited 322x in the literature
"Compared to CNT women and to men, and controlling for age, PERI and MENO groups exhibited increased indicators of AD endophenotype, including hypometabolism, increased Aβ deposition, and reduced gray and white matter volumes in AD-vulnerable regions ( p < 0.001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and peripher… (PloS one 2017) · cited 186x in the literature
"Both MENO and PERI groups exhibited reduced CMRglc in AD-vulnerable regions which was correlated with decline in mitochondrial COX activity compared to CNT (p's<0.001). A gradient in biomarker abnormalities was most pronounced in MENO, intermediate in PERI, and lowest in CNT (p<0.001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain im… (PloS one 2018) · cited 240x in the literature
"These findings indicate emergence and progression of a female-specific hypometabolic AD-endophenotype during the menopausal transition." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Research by Dr. Stephen Cunnane using C-11 acetoacetate PET shows that brain ketone utilization remains preserved in early to mild-mid stage Alzheimer's disease.
"his work looks at brain metabolism using a radioactive C-11 acetoacetate, which is a marker for the utilization of ketones. And what he has demonstrated is in individuals who do show those glucose hypometabolism or bioenergetic deficits, which we used to think was an indication of neuronal failure—that the reason the brain shows these deficits in glucose utilization is because the neurons were dying. Well, it turns out that's not true at all. That when ketones are supplied and you image the brain, it lights up in a very normal way, and that ketone utilization is preserved even in early to mild-mid stage Alzheimer's disease." (said at 0:20:43)
Dual-tracer PET imaging studies led by Dr. Stephen Cunnane using 11C-acetoacetate (a PET tracer for ketone metabolism) and 18F-FDG (for glucose metabolism) confirm that cerebral ketone uptake and utilization remain preserved in patients with mild-to-moderate Alzheimer's disease and mild cognitive impairment, despite significant regional glucose hypometabolism. When exogenous ketone supply is elevated (e.g., via ketogenic medium-chain triglyceride supplementation), brain ketone uptake increases proportionally in patients with mild-moderate Alzheimer's disease at rates comparable to healthy controls.
In a one-year study by Dr. Sarah Hallberg, patients achieved restoration of insulin sensitivity, medication reduction, and discontinuation of sulfonylureas across the entire interventional group.
"You know, in a one-year study was able to show restoration of insulin sensitivity, reduction of medication, discontinuing sulfonylureas in the entire interventional group." (said at 0:25:34)
The host's claim accurately reflects the published 1-year results of an open-label, non-randomized controlled clinical trial led by Dr. Sarah Hallberg (PMID 29417495). In 262 adults with type 2 diabetes receiving a continuous care intervention with carbohydrate restriction (nutritional ketosis), 1-year results demonstrated a 55% improvement in HOMA-IR (indicating restored insulin sensitivity), a significant decrease in diabetes medications (prescription of non-metformin diabetes medications dropped from 56.9% to 29.7%), and 100% discontinuation of sulfonylurea prescriptions across the intervention group.
An October 2018 study from the University of Texas demonstrated that individuals in midlife (in their 40s) in the top third of cortisol levels have brain shrinkage along with reduced memory and visual perception.
"She shared with me some data from October 2018 from the University of Texas. I'm sure you probably saw this data too, showing that in midlife, starting in your 40s in both men and women, stress has major effects on brain structure and function. So we know that women are more vulnerable than men. We know that high levels of stress, so if you take the people who have kind of the top third in terms of cortisol, the main hormone of stress, they have shrinkage of the brain. And I haven't seen a lot of data on that in women in their 40s. So I think this is really important. So it affects the structure of the brain, it reduces the volume of the brain, and it also is associated with reduced memory and visual perception." (said at 0:26:44)
A cross-sectional analysis from the Framingham Heart Study led by researchers at the University of Texas Health Science Center at San Antonio (published in Neurology in October 2018) examined 2,231 dementia-free participants with a mean age of 48.5 years. The authors found that individuals in the highest tertile of fasting morning cortisol had significantly lower total cerebral brain volume, reduced frontal and occipital gray matter volumes, and poorer performance on tests of memory and visual perception compared to those in the middle tertile. Furthermore, the inverse association between cortisol and total brain volume was statistically significant in women but not in men.
Low levels of cortisol are necessary for memory encoding, but high levels are toxic to the hippocampus.
"from that we learned that, yes, it is directly toxic to the hippocampus, but at very low levels cortisol actually is a virtual requirement for encoding memory." (said at 0:28:41)
Preclinical and mechanistic literature establishes an inverted-U relationship between glucocorticoids (such as cortisol and corticosterone) and hippocampal function. Basal or low glucocorticoid signaling is required for normal hippocampal synaptic plasticity and spatial memory encoding; blocking these receptors or removing adrenal steroids impairs memory. Conversely, prolonged exposure to high levels of glucocorticoids induces dendritic atrophy, neuroendangerment, and neuronal loss (neurotoxicity) specifically within the hippocampus.
- supports: Support for a bimodal role for type II adrenal steroid receptors in spatial memory. (Neurobiology of learning and memory 1999) · cited 200x in the literature
"The findings indicated that spatial memory was impaired when the Type II receptors were blocked (RU555) or highly occupied (corticosterone or RU362) and normal for the other treatment conditions. These data suggest that the Type II receptors may be responsible for the inverted U-shaped relationship between spatial memory and corticosterone levels reported by others." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Neurotoxicity of glucocorticoids in the primate brain. (Hormones and behavior 1994) · cited 518x in the literature
"Thus, hippocampal pyramidal neurons containing a high concentration of glucocorticoid receptors appear to be highly vulnerable to either hypercortisolemia caused by severe stress or to exposure to exogenous glucocorticoids." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. (Stress (Amsterdam, Netherlands) 1996) · cited 743x in the literature
"The first half of this review considers three types of GC effects: a) GC-induced atrophy, in which a few weeks' exposure to high GC concentrations or to stress causes reversible atrophy of dendritic processes in the hippocampus; b) GC neurotoxicity where, over the course of months, GC exposure kills hippocampal neurons; c) GC neuroendangerment, in which elevated GC concentrations at the time of a neurological insult such as a stroke or seizure impairs the ability of neurons to survive the insult." (abstract, results, passage verified)
pubmedfull study (doi)
The dentate gyrus of the hippocampus is an area of the brain capable of adult neurogenesis.
"that's the area of the brain, the dentate gyrus of the hippocampus, that regenerates. Who knew that?" (said at 0:30:27)
The statement accurately reflects established neuroscience literature. Adult neurogenesis in humans and mammalian models is well-documented to occur in specific niches of the adult brain, primarily the subgranular zone of the dentate gyrus within the hippocampus, where neural stem and progenitor cells continue to generate functional granule neurons throughout adulthood.
Lowering dietary sugar and refined carbohydrate intake induces ketone production and enhances brain-derived neurotrophic factor (BDNF).
"we eat a lower-sugar or lower-refined carbohydrate diet to emphasize the production of ketones to enhance brain-derived neurotrophic factor" (said at 0:30:41)
Diets low in carbohydrates/sugars, such as ketogenic diets, shift metabolism toward ketone production (specifically β-hydroxybutyrate, β-OHB). Human randomized controlled clinical trial data show that a 3-week ketogenic diet significantly increases circulating β-OHB as well as brain-derived neurotrophic factor (BDNF) levels by 47% compared to a standard diet (PMID: 40172923). Preclinical mechanistic studies also demonstrate that β-hydroxybutyrate acts directly as an endogenous histone deacetylase (HDAC) inhibitor to induce hippocampal *BDNF* gene expression (PMID: 27253067), and systematic reviews of clinical trials confirm that ketogenic diets generally elevate BDNF levels (PMID: 41519822).
- supports: Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the a… (eLife 2016) · cited 795x in the literature
"The metabolite β-hydroxybutyrate, which increases after prolonged exercise, induces the activities of Bdnf promoters, particularly promoter I, which is activity-dependent. We have discovered that the action of β-hydroxybutyrate is specifically upon HDAC2 and HDAC3, which act upon selective Bdnf promoters." (abstract, passage verified)
pubmedfull study (doi) - supports: A 3-Week Ketogenic Diet Increases Global Cerebral Blood Flow and Brain-Derived Neurotrophi… (The Journal of clinical endocrinology and metabolism 2025) · cited 6x in the literature
"A KD led to increased basal plasma β-OHB levels compared to the SDD (647 [418-724] vs 50 [50-60] μmol/L, P < .05), increased CBF by 22% (P = .02), and elevated BDNF levels by 47% (P = .04)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The effect of dietary interventions on brain-derived neurotrophic factor (BDNF) levels in … (BMC nutrition 2026) · cited 4x in the literature
"The study found varying effects: intermittent fasting and ketogenic diets generally increased BDNF, while other diets showed minimal or no impact." (abstract, results, passage verified)
pubmedfull study (doi)
Women diagnosed with polycystic ovary syndrome (PCOS) exhibit an altered gut microbiome and disrupted gut-brain axis compared to healthy controls.
"We know that women with PCOS have an altered microbiome. We know that gut-brain axis is not normal." (said at 0:26:40)
Multiple systematic reviews and meta-analyses of human observational studies demonstrate that women diagnosed with polycystic ovary syndrome (PCOS) exhibit significant gut microbial dysbiosis compared to healthy controls, characterized by reduced alpha diversity (e.g., lower Chao and Shannon indices) and alterations in relative bacterial abundances (PMID: 37739322, PMID: 37559119). Human clinical case-control studies and systematic reviews also confirm dysregulation of gut-brain axis mediators, including significantly lower serum levels of gut-brain signaling peptides such as ghrelin and serotonin, as well as altered gut microbiome-mediated neuroendocrine pathways (PMID: 42076786, PMID: 40967455).
- supports: Perturbations in gut microbiota composition in patients with polycystic ovary syndrome: a … (BMC medicine 2023) · cited 92x in the literature
"A significant decrease in microbial evenness and phylogenetic diversity was observed in PCOS patients when compared with control participants (Shannon index: SMD = - 0.27; 95% CI, - 0.37 to - 0.16... Gut dysbiosis in PCOS is associated with decreased diversity and alterations in bacteria involved in microbiota-host crosstalk." (abstract, results and conclusion)
pubmedfull study (doi) - supports: Alterations of gut microbiota biodiversity and relative abundance in women with PCOS: A sy… (Microbial pathogenesis 2023) · cited 24x in the literature
"Compared to the control group, the Chao index (WMD -28.88, 95% CI -45.78 to -11.98, I 2 = 100%), Shannon index (WMD -0.11, 95% CI -0.18 to 0.00, I 2 = 92.2%); and observed operational taxonomic units (OTUs) counts (WMD - 23.48, 95% CI -34.44 to -12. 53, I 2 = 99.6%) were significantly lower in women with PCOS. The relative abundance of Bacteroidaceae was significantly higher... We demonstrated the alpha diversity of gut microbiota and the relative abundance of Bacteroidaceae in women with PCOS are altered." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: Metabolic-endocrine correlates of gut-brain axis mediators in polycystic ovary syndrome: A… (Journal of neuroendocrinology 2026) · cited 1x in the literature
"Polycystic ovary syndrome (PCOS) is increasingly recognized as a neuro-metabolic disorder involving disrupted signaling between the brain-gut axis and reproductive system... Women with PCOS had significantly higher serum kisspeptin levels and lower ghrelin and serotonin levels compared to controls (p < .05)... indicate the central role of hypothalamic-gut axis dysfunction, particularly in lean PCOS phenotypes." (abstract, background and results)
pubmedfull study (doi)
Gut bacterial beta-glucuronidase deconjugates estrogen metabolites, and gut dysbiosis can cause estrogen recirculation and elevated estradiol levels.
"We know that women tend to modulate estrogen levels differently than men, and much of that is governed by a certain set of bacteria. And what we're talking about here is an enzyme called beta-glucuronidase. And so the idea with estrogen as the master regulator in the female body is that you want to produce it, you want to use it, and then you want to get rid of it. You don't want it recirculating in the body over and over again like bad karma. And if you have kind of the dysbiosis, the wrong balance of microbes in your gut, you're more likely to keep recycling it and for your estradiol levels to climb, to get too high." (said at 0:36:15)
Published literature supports the role of the gut microbiome—specifically the 'estrobolome'—in estrogen metabolism and recirculation. Estrogens are conjugated in the liver (e.g., glucuronidation) and excreted via bile into the gastrointestinal tract. Bacterial enzymes, predominantly microbial β-glucuronidases (and sulfatases), deconjugate these metabolites back into free estrogens, permitting their reabsorption across the gut mucosa into the enterohepatic circulation. Alterations or shifts in the composition and enzymatic activity of the gut microbiota can increase deconjugation and reabsorption, raising systemic free estradiol levels.
- supports: The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. (Journal of the National Cancer Institute 2016) · cited 533x in the literature
"In this review, we discuss how the intestinal bacterial microbiome and in particular how an 'estrobolome,' the aggregate of enteric bacterial genes capable of metabolizing estrogens, might affect women's risk of developing postmenopausal estrogen receptor-positive breast cancer." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Mass spectrometric profiling of primary estrogens and estrogen metabolites in human stool … (Molecular and cellular endocrinology 2025) · cited 8x in the literature
"These results support the hypothesis that gut microbial β-glucuronidase and arylsulfatase control the deconjugation of gut estrogens while modulating systemic levels through the uptake and recirculation of these deconjugated estrogens." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Impact of long-term medication on estrobolome-associated β-glucuronidase and sulfatase act… (Maturitas 2026) · cited 2x in the literature
"The estrobolome, a subset of microbes with β-glucuronidase (GUS) and sulfatase activities, regulates estrogen homeostasis through deconjugation and enterohepatic recycling, thereby influencing systemic estrogen availability." (abstract, background, passage verified)
pubmedfull study (doi)
The estrogen 4-quinone metabolic pathway is genotoxic and causes mutations and DNA damage.
"And there's even a 4-quinone pathway that is especially genotoxic, so it can cause mutations and damage to DNA." (said at 0:39:35)
Preclinical in vitro and animal studies demonstrate that metabolism of estrogens via 4-hydroxylation leads to the formation of catechol estrogen-3,4-quinones (CE-3,4-Q). These electrophilic metabolites covalently react with DNA purine bases, primarily forming depurinating adducts (4-OHE1/E2-1-N3Ade and 4-OHE1/E2-1-N7Gua). The resulting apurinic sites and redox-cycling reactive oxygen species cause DNA strand breaks, base damage, and error-prone repair mutations.
Paleolithic humans are estimated to have consumed up to 105 grams of dietary fiber per day.
"It's been estimated that our Paleolithic ancestors may have gotten as much as 105 grams of fiber a day." (said at 0:41:45)
Nutritional and anthropological reconstructions of ancestral diets estimate that Paleolithic humans consumed substantially higher amounts of dietary fiber than modern populations, with widely cited models (such as those by S. Boyd Eaton, Melvin Konner, and colleagues) calculating daily fiber intakes of approximately 100 to 104–105 grams per day depending on the estimated plant-to-animal subsistence ratios. Because these figures are indirect theoretical estimates based on archaeological evidence, botanical analysis, and ethnographic records of recent hunter-gatherer societies rather than direct observational measurements, the certainty of the historical intake estimates is very low.
A JAMA study published around 2019 demonstrated that consumption of ultra-processed foods was associated with a 14% increased risk of all-cause mortality.
"I'm certainly sure you're aware of the study that came out just two weeks ago demonstrating that consumption of these ultra-processed foods was associated, in JAMA, was associated with an increased risk of all-cause mortality of 14%." (said at 0:42:45)
A 2019 observational cohort study published in JAMA Internal Medicine (Schnabel et al., 2019) evaluated 44,551 French adults from the NutriNet-Santé cohort over a median follow-up of 7.1 years. The study found that each 10% increment in the proportion of ultra-processed food consumed was associated with a 14% higher risk of all-cause mortality (adjusted hazard ratio 1.14, 95% CI 1.04–1.27, P = .008). Because this is an observational cohort design, the GRADE certainty for a direct causal relationship is low due to potential residual confounding.
80% of Americans eat food in their car.
"I was horrified to read this statistic that 80% of Americans eat in their car." (said at 0:43:35)
Published sociological research on mobile eating patterns reports that over 80% of North Americans regularly eat in their cars, aligning with the cited statistic.
Perceptions of social isolation, rejection, or conflict trigger the immune system to ramp up inflammation even in the absence of actual physical injury.
"what happens with the way our DNA evolved is that if you have this perception of social isolation, social rejection, or social conflict, it cues the immune system to prepare for physical injury, meaning that it ramps up and becomes inflamed even in the absence of any sort of physical injury actually occurring." (said at 0:44:10)
Published research in human social genomics confirms that perceived social isolation, rejection, and social threat activate a conserved transcriptional response to adversity (CTRA) in leukocytes. This pattern involves the up-regulation of pro-inflammatory gene expression and the down-regulation of type I interferon and antibody-related genes via sympathetic nervous system signaling, even without physical injury or acute microbial infection. Evolutionary models and empirical human and non-human primate studies demonstrate that the nervous system interprets social threat as a cue to bias immune transcription toward wound healing and antibacterial inflammatory pathways.
- supports: Human social genomics. (PLoS genetics 2014) · cited 423x in the literature
"In leukocytes, diverse types of social adversity evoke a common conserved transcriptional response to adversity (CTRA) characterized by increased expression of proinflammatory genes and decreased expression of genes involved in innate antiviral responses and antibody synthesis. Mechanistic analyses have mapped the neural "social signal transduction" pathways that stimulate CTRA gene expression in response to social threat and may contribute to social gradients in health." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Myeloid differentiation architecture of leukocyte transcriptome dynamics in perceived soci… (Proceedings of the National Academy of Sciences of the United States of America 2015) · cited 317x in the literature
"Five longitudinal leukocyte transcriptome surveys in 141 older adults showed up-regulation of the sympathetic nervous system (SNS), monocyte population expansion, and up-regulation of the leukocyte conserved transcriptional response to adversity (CTRA). Mechanistic analyses in a macaque model of perceived social isolation confirmed CTRA activation and identified selective up-regulation of the CD14(++)/CD16(-) classical monocyte transcriptome, functional glucocorticoid desensitization, down-regulation of Type I and II interferons, and impaired response to infection by simian immunodeficiency virus (SIV)." (abstract, results, passage verified)
pubmedfull study (doi)
Carrying one APOE4 allele increases the risk of developing Alzheimer's disease up to fivefold, and carrying two alleles increases the risk twelvefold.
"For example, the APOE4 allele is associated with as much as a fivefold increased risk without any other intervention for developing that condition. If you carry both, the risk is increased twelvefold." (said at 0:48:25)
Large-scale meta-analyses demonstrate that carrying one APOE4 allele increases the risk of developing Alzheimer's disease approximately 3- to 5-fold depending on population and ethnicity (e.g., an odds ratio of 3.2 in Caucasians and 5.6 in Japanese populations relative to ε3/ε3). Carrying two copies of the APOE4 allele increases the risk approximately 12- to 15-fold (odds ratio of 14.9 in Caucasians, 95% CI 10.8–20.6). The host's statement accurately reflects these established epidemiological risk estimates.
- supports: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype an… (JAMA ) · cited 4676x in the literature
"Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes epsilon2/epsilon4 (OR=2.6, 95% CI=1.6-4.0), epsilon3/epsilon4 (OR=3.2, 95% CI=2.8-3.8), and epsilon4/epsilon4 (OR=14.9, 95% CI= 10.8-20.6)... The APOE epsilon4-AD association in Japanese subjects was stronger than in Caucasian subjects (epsilon3/epsilon4: OR=5.6, 95% CI=3.9-8.0; epsilon4/epsilon4: OR=33.1, 95% CI=13.6-80.5)." (abstract, results, passage verified)
pubmed
Between 20% and 25% of Americans carry the APOE4 allele.
"And in the context of Alzheimer's, then if you are a carrier of the APOE4 allele, you have increased risk—we're talking 20 to 25% of Americans—then what should you do?" (said at 0:49:30)
Large epidemiological and biobank studies in the United States confirm that approximately 20% to 25% of the population carries at least one copy of the APOE-ε4 allele, although exact carrier frequencies vary somewhat by race and ethnic ancestry (e.g., ~14% in Filipino Americans to ~25% in non-Latino White Americans).
Approximately 80% of autoimmune conditions occur in women.
"But the downside of unbridled inflammation, which is also affected by lifestyle choices, is increased risk for Alzheimer's and autoimmune conditions, which are, you know, 80% of which are found in women, with a few exceptions." (said at 0:53:10)
Epidemiological reviews and immunological literature widely cite that approximately 78% to 80% of individuals diagnosed with autoimmune diseases are women, although the female-to-male ratio varies considerably across specific conditions (ranging from near-equal distributions in conditions like type 1 diabetes to around 85-90% female predominance in systemic lupus erythematosus, Sjögren's syndrome, and autoimmune thyroid disease). More recent large-scale electronic health record analyses report aggregate female prevalence around 63% to 78%, confirming a strong overall female skew in autoimmune disease burden.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.